Tonix Pharmaceuticals Files 8-K Under 'Other Events'
Ticker: TNXP · Form: 8-K · Filed: Feb 21, 2025 · CIK: 1430306
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: TNXP
TL;DR
TNXP filed an 8-K for 'Other Events' on Feb 20. Details TBD.
AI Summary
Tonix Pharmaceuticals Holding Corp. filed an 8-K on February 21, 2025, reporting an event on February 20, 2025. The filing is categorized under 'Other Events' and does not specify any material agreements, acquisitions, or executive changes.
Why It Matters
This filing indicates a routine update or event for Tonix Pharmaceuticals, but without specific details, its immediate impact on the company or investors is unclear.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and lacks specific material information that would indicate a significant risk.
Key Players & Entities
- Tonix Pharmaceuticals Holding Corp. (company) — Registrant
- February 20, 2025 (date) — Date of earliest event reported
- February 21, 2025 (date) — Filing date
- Nevada (jurisdiction) — State of Incorporation
- 26 Main Street, Chatham, New Jersey 07928 (address) — Principal executive offices
FAQ
What specific event is reported under 'Other Events' in this 8-K filing?
The filing does not specify the nature of the 'Other Events' beyond categorizing it as such.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on February 20, 2025.
What is the filing date of this 8-K?
This 8-K filing was made on February 21, 2025.
What is the principal executive office address for Tonix Pharmaceuticals Holding Corp.?
The principal executive offices are located at 26 Main Street, Chatham, New Jersey 07928.
What is the Commission File Number for Tonix Pharmaceuticals Holding Corp.?
The Commission File Number is 001-36019.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 21, 2025 regarding Tonix Pharmaceuticals Holding Corp. (TNXP).